No information is available on the clinical use of lenvatinib during breastfeeding. Because lenvatinib is more than 98% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 28 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during lenvatinib therapy and for at least 1 week after the last dose.
关于乐伐替尼在母乳喂养期间的临床应用尚无可用信息。由于乐伐替尼与血浆蛋白的结合率超过98%，乳汁中的含量可能较低。然而，其半衰期约为28小时，可能会在婴儿体内蓄积。制造商建议在乐伐替尼治疗期间及最后一剂后至少1周内停止母乳喂养。
